SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE has emerged as a trending meme coin, triggering a polarized debate among traders over whether it represents a legitimate high-growth asset or a blatant pump-and-dump scheme. While some investors are actively accumulating the token in hopes of repeating past meme coin rallies, others are dismissing the project as a low-quality scam with unsustainable price action.

Fundrise Innovation Fund LLC. - Common Shares of Limited Liability Company Interests

Fundrise Innovation Fund 

VCX is experiencing significant volatility and trending attention as retail investors speculate on its high-profile private company portfolio, including holdings like SpaceX and OpenAI. The stock is seeing heavy trading activity and community discussion centered on the impact of a six-month lockup period, which has limited available float and fueled intense debate over its valuation relative to its underlying net asset value.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is seeing a surge in investor interest and trading volume driven by persistent market speculation regarding potential M&A activity. While retail sentiment remains highly divided between long-term holders hopeful for a buyout premium and skeptics wary of the lack of official confirmation, the unusual after-hours price action has prompted significant discussion across community forums.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market volatility remains high as traders react to conflicting reports regarding U.S.-Iran diplomatic talks, with many observers expressing skepticism toward official announcements given the recent escalation in energy infrastructure attacks. Community discussions are dominated by concerns over geopolitical instability, accusations of market manipulation by political figures, and the potential for a broader energy crisis impacting long-term economic stability.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is capturing significant investor attention as it reports earnings and navigates a high-profile merger with Valaris, creating a combined entity with a massive multi-billion dollar backlog. Community sentiment remains polarized, with bullish investors highlighting improved fleet utilization and debt reduction as long-term catalysts, while others debate the impact of the merger dilution and the company's historical volatility.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors aggressively position themselves ahead of the company's earnings release, with heavy community speculation focusing on potential updates regarding NASA's Lunar Terrain Vehicle contract. Sentiment remains divided between those betting on transformative revenue growth and a potential short squeeze, and those highlighting the execution risks inherent in the aerospace sector.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is seeing increased market attention driven by a combination of housing supply fluctuations, evolving macro rate expectations, and integration with generative AI tools like ChatGPT. Community members remain actively divided, with some highlighting the stock as an undervalued opportunity for long-term recovery, while others express caution regarding ongoing antitrust litigation and intensified competition from tech giants entering the real estate listings space.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is gaining momentum as investors closely monitor weekly prescription data for its fibromyalgia drug, Tonmya, which is showing signs of early adoption and patient refill retention. Community discussion remains heavily focused on the company's recent leadership insider purchases, anticipation for upcoming quarterly results, and strategic speculation regarding potential partnerships or buyouts within the CNS sector.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is trending as investors weigh potential catalysts from the anticipated Schedule 3 rescheduling of cannabis against ongoing skepticism regarding the company's aggressive acquisition strategy and its transition into the beverage sector. The community is actively debating the timing and impact of federal regulatory shifts, with many retail investors expressing frustration over long-term performance while others remain hopeful for a short-squeeze driven by high short interest and sector-wide volatility.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI is currently a top trending ticker following a strong Q4 earnings report, updated FY26 revenue guidance, and the announcement of new U.S. Navy and Air Force defense contracts. The community is sharply divided between retail traders betting on a potential short squeeze due to high short interest and long-term investors bullish on the company's strategic pivot into integrated autonomous defense systems.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

CLVSQ
Clovis Oncology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLVSQ News

CLVSQClovis Oncology Inc